偏头痛的新疗法......及其他研究

The BMJ Pub Date : 2024-09-12 DOI:10.1136/bmj.q1967

Tom Nolan

{"title":"偏头痛的新疗法......及其他研究","authors":"Tom Nolan","doi":"10.1136/bmj.q1967","DOIUrl":null,"url":null,"abstract":"Tom Nolan reviews this week’s research You never have to wait too long for a trial of a new drug for migraine. The latest one is Lu AG09222, a monoclonal antibody to pituitary adenylate cyclase-activating polypeptide (PACAP). The phase 2 trial recruited adults with migraine with an average of 16.7 migraine days per month and for whom two to four preventive treatments had failed. Those given a single infusion of Lu AG09222 750 mg had an average of 6.2 fewer migraine days over the following month, compared with 4.2 fewer in the placebo group (a between-group difference of two days (95% confidence interval −3.8 to −0.3)). With this positive phase 2 result, it’s time for Lu AG09222 to PACAP its bags and go to phase 3. N Engl J Med doi:10.1056/NEJMoa2314577 Infectious disease specialists like to keep fit by lifting heavy parcels of …","PeriodicalId":22388,"journal":{"name":"The BMJ","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New treatments for migraine … and other research\",\"authors\":\"Tom Nolan\",\"doi\":\"10.1136/bmj.q1967\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tom Nolan reviews this week’s research You never have to wait too long for a trial of a new drug for migraine. The latest one is Lu AG09222, a monoclonal antibody to pituitary adenylate cyclase-activating polypeptide (PACAP). The phase 2 trial recruited adults with migraine with an average of 16.7 migraine days per month and for whom two to four preventive treatments had failed. Those given a single infusion of Lu AG09222 750 mg had an average of 6.2 fewer migraine days over the following month, compared with 4.2 fewer in the placebo group (a between-group difference of two days (95% confidence interval −3.8 to −0.3)). With this positive phase 2 result, it’s time for Lu AG09222 to PACAP its bags and go to phase 3. N Engl J Med doi:10.1056/NEJMoa2314577 Infectious disease specialists like to keep fit by lifting heavy parcels of …\",\"PeriodicalId\":22388,\"journal\":{\"name\":\"The BMJ\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The BMJ\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmj.q1967\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The BMJ","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmj.q1967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

汤姆-诺兰（Tom Nolan）回顾本周研究偏头痛新药试验无需等待太久。最新的试验是Lu AG09222，一种垂体腺苷酸环化酶激活多肽（PACAP）的单克隆抗体。这项 2 期试验招募了患有偏头痛的成人患者，他们平均每月有 16.7 天偏头痛发作，并且接受过两到四次预防性治疗均告失败。在接下来的一个月里，单次输注Lu AG09222 750毫克的患者平均偏头痛天数减少了6.2天，而安慰剂组则减少了4.2天（组间差异为2天（95%置信区间-3.8至-0.3））。有了这一积极的二期研究结果，Lu AG09222公司就可以背起行囊进入三期研究了。N Engl J Med doi:10.1056/NEJMoa2314577 传染病专家们喜欢通过搬运沉重的包裹来保持身体健康...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

New treatments for migraine … and other research

Tom Nolan reviews this week’s research You never have to wait too long for a trial of a new drug for migraine. The latest one is Lu AG09222, a monoclonal antibody to pituitary adenylate cyclase-activating polypeptide (PACAP). The phase 2 trial recruited adults with migraine with an average of 16.7 migraine days per month and for whom two to four preventive treatments had failed. Those given a single infusion of Lu AG09222 750 mg had an average of 6.2 fewer migraine days over the following month, compared with 4.2 fewer in the placebo group (a between-group difference of two days (95% confidence interval −3.8 to −0.3)). With this positive phase 2 result, it’s time for Lu AG09222 to PACAP its bags and go to phase 3. N Engl J Med doi:10.1056/NEJMoa2314577 Infectious disease specialists like to keep fit by lifting heavy parcels of …

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The BMJ

自引率

0.00%

发文量